RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY27 results · Apr–Jun 2026
RPG Life Sciences reported revenue from operations of ₹195.69 crore and net profit of ₹30.76 crore for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 195.69 | — | — | 176.89 | +10.6% |
| Other income | 4.70 | — | — | 12.40 | −62.1% |
| Total income | 200.39 | — | — | 189.29 | +5.9% |
| Profit before tax | 41.46 | — | — | 40.20 | +3.1% |
| Net profit for the period | 30.76 | — | — | 29.90 | +2.9% |
| EPS, basic (₹) | 18.60 | — | — | 18.08 | +2.9% |
| Net margin (%) | 15.7 | — | 16.9 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 195.69 | 168.92 | +15.8% | 176.89 | +10.6% |
| Other income | 4.16 | 5.23 | −20.5% | 12.36 | −66.3% |
| Total income | 199.85 | 174.15 | +14.8% | 189.25 | +5.6% |
| Profit before tax | 41.21 | 35.43 | +16.3% | 40.20 | +2.5% |
| Net profit for the period | 30.57 | 26.29 | +16.3% | 29.90 | +2.2% |
| EPS, basic (₹) | 18.49 | 15.90 | +16.3% | 18.08 | +2.3% |
| Net margin (%) | 15.6 | 15.6 | 16.9 |
Consolidated
- Filed with BSE
- 28 Jul 2026, 20:20 IST
- Board meeting
- 28 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jul 2026, 20:20 IST
- Board meeting
- 28 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE